2021
Laboratory evaluation and prognostication among adults and children with CEBPA‐mutant acute myeloid leukemia
Mendoza H, Podoltsev NA, Siddon AJ. Laboratory evaluation and prognostication among adults and children with CEBPA‐mutant acute myeloid leukemia. International Journal Of Laboratory Hematology 2021, 43: 86-95. PMID: 34288448, DOI: 10.1111/ijlh.13517.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCEBPA mutant acute myeloid leukemiaAcute myeloid leukemiaCEBPA mutationsMyeloid leukemiaLeukemogenic mutationsPositive prognostic impactSingle CEBPA mutationsSimilar survival outcomesNegative prognostic effectFLT3-ITD mutationLaboratory evaluationWild-type CEBPAMultiparameter flow cytometryGermline CEBPA mutationsFavorable prognosisPrognostic impactMutation presencePrognostic effectRisk stratificationSurvival outcomesGATA2 mutationsDistinct subtypesMolecular findingsCEBPA geneFlow cytometry
2015
Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia
Schulz W, Durant T, Rinder H, Tormey C, Torres R, Smith B, Hager K, Howe J, Siddon A. Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia. Blood 2015, 126: 1385. DOI: 10.1182/blood.v126.23.1385.1385.Peer-Reviewed Original ResearchDe novo acute myeloid leukemiaNovo acute myeloid leukemiaAcute myeloid leukemiaMolecular clonalityAML patientsTumor heterogeneityMyeloid leukemiaNext-generation sequencingNormal-risk subjectsAdverse prognostic indicatorTime of diagnosisFurther prospective studiesLong-term outcomesFLT3-ITD mutationHigh-risk groupChoice of therapyFirst prospective evidenceLimited clinical utilityHigh-risk classificationEarly survivalStudy patientsOverall survivalPatient agePatient subsetsInitial diagnosis